Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTER: tislelizumab + bevacizumab + TAS-102 + SBRT in MSS metastatic colorectal cancer (third-line)
ChiCTR2300075853Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, bevacizumab and trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: median progression-free survival and objective response rate. Started Sep 2023; status: recruiting.
02
Drugs
tislelizumabbevacizumabtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300075853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075853.